Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > asco abstract info

<< Previous

Bullboard Posts

Next >>

Comment by Snowdrifton Jun 03, 2023 11:28pm

257 Views

Post# 35478927

RE:RE:RE:RE:RE:RE:asco abstract info

Azzak, that's not quite what was tweeted.

The exact quote was "Join us Monday June 5 at 8 am ET for a discussion of the exciting BreastCancer data from this study."

So they're not saying they have news on the results. They're just asking people to watch the KOL discussion about the results.

Regards,
Snowdrift

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario